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Background: Pleomorphic Acinetobacter baumannii is a highly
successful nosocomial pathogen. It is an obligate aerobic, gramneg-
ative bacteria that causes nosocomial pneumonia and meningitis
among hospitalized patients. Broad range resistance to multiple
antibiotics has been the biggest challenge to treat A. bauman-
nii infection. Here, we described the production, characterization,
puriﬁcation and identiﬁcation of monoclonal antibody speciﬁc
against the multi-drug resistant A. baumannii.
Methods & Materials: BALB/c mices were immunized with
formaldehyde-ﬁxed A. baumannii M28-47 strain. The spleen was
removed and fused with myeloma cells. A series of monoclonal
antibodies (mAb) speciﬁc to A. baumannii were produced. Char-
acterization of the mAb was performed using enzyme-linked
immunosorbent assay (ELISA) with subclass speciﬁc goat antisera.
Antibodies were puriﬁed by using the protein G-linked magnetic
beads. SDS-PAGE and immunoblot were performed to conﬁrm the
presence of the heavy and light chain of IgG of the puriﬁed anti-
body. Mass spectrometry was used to further conﬁrm the identity
of the antibody. Immunoblotting was performed to detect the A.
baumannii protein.
Results: All the hybridoma clones produced IgG1 subclass anti-
bodies. SDS-PAGE of the puriﬁed hybridoma antibody showed the
presence of the antibody heavy chain and light chain. The presence
was also conﬁrmed by ELISA, immunoblot and mass spectrometry.
All the puriﬁed antibodies detected A. baumannii protein prepared
on nitrocellulose membrane from A. baumannii cell lysate.
Conclusion: Monoclonal antibodies speciﬁc against A. bauman-
nii was successfully prepared. This mAb could be useful as reagents
for studying A. baumannii.
http://dx.doi.org/10.1016/j.ijid.2014.03.1130
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Recurrent urinary tract infection (UTI) in adult
females: Long term efﬁcacy of antimicrobial
prophylaxis and/or immunotherapy
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Background: The objective of this multicenter study was to
investigate the long – term preventive effect of chemoprophylaxis
with low-dose ﬂuoroquinolones and/or immunotherapy inwomen
with recurrent UTI. Both Uro – Vaxom (OM – 89) and Luivac are
extracts of bacterial components with complex immunostimulat-
ing activity.
Methods & Materials: Adult female patients with at least 3
documented episodes of UTI in a previous year were enrolled in
this 12 –months, multicenter study. Patients received continuous
chemoprophylaxis with low –dose ciproﬂoxacin (125mg orally
every other day) and /or immunotherapy with either Uro-Vaxom
or Luivac. Primary efﬁcacy criteria were number of UTI episodes
over the 12 months treatment period.
Results: A total of 178 patients were treated, 89 in the Uro
– Vaxom and 89 in the Luivac group, respectively. Mean rate
of post baseline UTIs decreased signiﬁcantly in both treatment
groups: in Uro –Vaxom group from 3.54 to 0.48 episode / patient /
year and in Luivac group from 3.63 to 0.41 episode /patient/ year
(p <0.001). There were 67.1% patients treated with combination
of immunotherapy and quinolone prophylaxis vs. 52.7% patients
treated with immunotherapy only, who were UTI – free in 12 –
months study period (p=0.04). In the subgroup receiving contin-
uous antimicrobial prophylaxis with ciproﬂoxacin (125mg orally
every other day), selection of quinolone – resistant strains was
observed in 9 patients (ESBL – producing strains of E. coli and Kleb-
siella pneumoniae). After 5-years follow–up, there remained65.0%
patients UTI – free in this study period.
Conclusion: These results conﬁrm that immunotherapy ismore
safe and almost as effective as low-dose quinolone prophylaxis
in prevention of recurrent UTI. Selection of quinolone – resistant
strains is a potential threat for patients on long-term quinolone
prophylaxis.
http://dx.doi.org/10.1016/j.ijid.2014.03.1131
